Investor Presentation
Investor Presentation
Brisbane, May 11, 2017 AEST (ABN Newswire) - Oventus Medical Ltd (ASX:OVN) is pleased to provide the Company's latest Investor Presentation.

Oventus Overview

Oventus' core technology is the 3D Printed patented airway

Oventus Airway Technology is the only technology that addresses resistance and obstructions at all levels of the airway enhancing airflow and enabling improved treatment outcomes.

This technology has been shown to make both oral appliance therapy and CPAP therapy more effective and/or better tolerated.

This technology is an enabling technology that can be deployed in competition with or in conjunction with existing technologies.

Oventus Airway Technology can be incorporated into both oral appliances and CPAP improving patient outcomes, negating the need for surgical intervention and providing diagnostic and monitoring solutions in one platform - the NEXUS in the treatment of OSA.

Progress over the past year has been strong

- Product Development
- Manufacturing setup with certification
- Additional clinical evidence
- Regulatory clearance for O2Vent T followed by launch in Australia and more recently US
- Progress made for China market - a significant opportunity
- Listing on ASX 07/2016 + successful with Aust. Govt. grant 02/2017

Our aim: to be cash positive by 2019

Key Success Measures
- Global roll out through partnerships
- Complete product range with expanded independent clinical evidence, with KOLs
- Scaled manufacturing for a broader customer base

To view the full presentation, please visit:

About Oventus Medical Ltd

Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

A clinical study completed earlier this year showed the company's first generation product the O2Vent Mono(TM) is successful in treating OSA and that snoring was either eliminated or significantly reduced to 100 per cent of patients. The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep. It also improves oxygen levels for patients.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.



Neil Anderson
Managing Director and Chief Executive Officer
M: +61-403-003-475

Dr Chris Hart
Clinical Director and Founder
M: +61-409-647-496

Related Companies

Oventus Medical Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 7) (Last 30 Days: 40) (Since Published: 2001) 

Oventus Medical Ltd NEWS: RECENT VISITS (2373)